JP Morgan Chase
BIVV

JP Morgan Chase’s Bioverativ Inc. Common Stock BIVV Stock Holding History

JP Morgan Chase’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-958,676
Closed -$51.7M – 5787
2017
Q4 		$51.7M Buy
958,676
+693,074
+261% +$37.9M 0.01% 970
2017
Q3 		$15.1M Buy
265,602
+1,595
+0.6% +$93.4K ﹤0.01% 1691
2017
Q2 		$15.9M Buy
264,007
+73,871
+39% +$4.21M ﹤0.01% 1621
2017
Q1 		$10.4M Buy
+190,136
New +$9.37M ﹤0.01% 1914

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

JP Morgan Chase's BIVV Position: Q1 2018 in Review

JP Morgan Chase sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 958,676 shares — an estimated $51.7M sold.

JP Morgan Chase first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $51.7M in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • JP Morgan Chase reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • JP Morgan Chase sold 958,676 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $51.7M.
  • JP Morgan Chase first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • JP Morgan Chase's Bioverativ Inc. Common Stock position peaked at $51.7M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on JP Morgan Chase's 13F filing for Q1 2018, filed 10 May 2018.